RedHill Biopharma Ltd 6-K, filed Mar 23, 2020

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of March 2020

Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

21 Ha'arba'a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Attached hereto and incorporated by reference herein is the following:

Exhibit 1: Registrant's press release entitled: “RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on March 26”

This Form 6-K is incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122) and on July 24, 2019 (File No. 333-232776) and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on February 25, 2016 (Registration No. 333-209702), on July 23, 2018 (File No. 333-226278) and on July 24, 2019 (File No. 333-232777).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 1

RedHill Biopharma toPresent at Virtual Life Sciences Investor Forum on March 26

TEL-AVIV, Israel and RALEIGH, N.C., March 23, 2020 RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that Guy Goldberg, RedHill's Chief Business Officer, will present a corporate overview at the Virtual Life Sciences Investor Forum on Thursday, March 26, 2020, at 9:30 a.m. EDT.

This will be a live, online presentation where the audience is invited to ask the Company questions in real-time. The live broadcast and Q&A session can be accessed via the Company's website, http://ir.redhillbio.com/events. Please access the website at least 15 minutes ahead of the presentation to register.

A replay of the presentation will be available for 30 days via the Company’s website: http://ir.redhillbio.com/events.

About RedHill BiopharmaRedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs, Talicia^®^ for the treatment of Helicobacter pylori (H. pylori) infection in adults^1^ and Aemcolo^®^ for the treatment of travelers’ diarrhea in adults^2^. RedHill acquired rights to Movantik^®^for opioid-induced constipation in adults^3^. The acquisition remains subject to certain customary closing conditions and regulatory clearances. RedHill’s key clinical late-stage development programs include: (i) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (ii) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (iii) RHB-102 (Bekinda^®^), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) Opaganib (Yeliva^®^), a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 1/2a study for cholangiocarcinoma; (v) RHB-106, an encapsulated bowel preparation, and (vi) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases. More information about the Company is available at www.redhillbio.com.

_______________________

^1^ Full prescribing information for Talicia^®^ (omeprazole magnesium, amoxicillin, and rifabutin) is available at: www.Talicia.com

^2^ Full prescribing information for Aemcolo^®^ (rifamycin) is available at: www.Aemcolo.com.

^3^ Full prescribing information for Movantik® (naloxegol) is available at: www.Movantik.com.

About Life Sciences Investor Forum

Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet and present directly with investors.

A real-time solution for investor engagement, Life Sciences Investor Forum is part of Intrado’s suite of investor relations services specifically designed for more efficient Investor Access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network. Learn more about the event at www.lifesciencesinvestorforum.com.

About Intrado

Intrado, Formerly West, is an innovative, cloud-based, global technology partner to clients around the world. Our solutions connect people and organizations at the right time and in the right ways, making those mission-critical connections more relevant, engaging, and actionable-turning Information to Insight.

This press release contains “forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,”“may,” “will,” “plans,” “expects,” “anticipates,” “projects,”“predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risksand uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently,actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertaintiesinclude, without limitation, risks related to the timing of hiring sales representatives as well as risks and uncertainties associatedwith (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinicaltrials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its therapeutic candidatesand its FDA-approved products; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or tosuccessfully complete its preclinical studies or clinical trials or the development of a commercial companion diagnostic for thedetection of MAP; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’sreceipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback;(iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidatesand Talicia^®^; (v) the Company’s ability to successfully commercialize and promote Talicia^®^and Aemcolo^®^and following closing of the acquisition, Movantik^®^;(vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire productsapproved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities;(viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtainedwith its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’sbusiness model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able toestablish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its businesswithout infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual propertydefaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirementsand needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs underthe Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry;and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and therisk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securitiesand Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on March 4, 2020. All forward-lookingstatements included in this press release are made only as of the date of this press release. The Company assumes no obligationto update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unlessrequired by law.